Last updated on September 2020

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)


Brief description of study

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

Clinical Study Identifier: NCT04437511

Find a site near you

Start Over

Abington Neurological Associates

Abington, PA United States
3.62miles
  Connect »

Abington Neurological Associates, Ltd.

Abington, PA United States
3.62miles
  Connect »

Clinical Trial Center, LLC, Psychiatry

Jenkintown, PA United States
5.78miles
  Connect »

The Clinical Trial Center, LLC

Jenkintown, PA United States
5.78miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.